All News

New findings add to the understanding of the patient experience in axial spondyloarthritis (axSpA), which can help inform patient-centered clinical care.

The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021.

World Dense Breast Day emphasizes the need for awareness and advocacy for individuals with dense breasts, which can negatively impact mammogram results and increase breast cancer risk.

The 21st annual meeting of the International Myeloma Society (IMS) takes place September 25-28, 2024, in Rio de Janeiro, Brazil.

New research highlights increased stroke, heart attack, and heart failure risks in cancer survivors, especially those treated with chemotherapy.

"As CMMI continues to test new equity adjustments, it is important that changes be grounded in scientific principles with extensive testing and validation to ensure the tightest linkage to social needs and health outcomes for underserved communities across the entire US," authors wrote.

Joseph Alvarnas, MD, of City of Hope, discusses how he envisions the future of cancer care over the next decade.

People with the most weekend catch-up sleep had a 20% lower risk of heart disease, especially those who were sleep-deprived during the week.

Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms.

A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), adding to the literature on nutritional and metabolic complications linked to SMA.

A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL).

The Center on Health Equity & Access covers news spanning health policy, politics, and clinical research, while featuring interviews with expert insights.

Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and progression-free survival (PFS) in patients with epithelial ovarian cancer

Domestic and international financial challenges in maternity care highlight the need for payment reforms to reduce out-of-pocket costs and better protect pregnant women from financial strain.

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot receive an autologous stem cell transplant to treat their newly diagnosed multiple myeloma.

Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, and their potential downsides is key to making informed decisions.

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the US—Caremark, Express Scripts, and Optum Rx—of inflating insulin costs for patients, prompting renewed calls for PBM reform.

The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma.

Patients with sickle cell anemia (SCA) and persistent albuminuria (PA) exhibited significantly higher levels of urinary angiotensinogen (AGT).

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) offered an allogenic hematopoietic stem cell transplantation.

Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses challenges to the optimal treatment of PAH, explained the researchers.

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

More than 25 million people lost their Medicaid coverage during the unwinding process conducted by all states following the pandemic.

Findings from a new study reveal significant racial differences in skin biopsy frequency for psoriasis diagnosis, indicating potential diagnostic challenges, particularly for Black patients.

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL).

The impact alopecia areata (AA) has on patients' health-related quality of life (HRQOL) may not be accurately measured with EQ-5D-5L, suggesting the need for alternative assessments.

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment options.

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF).